Education
About Us
Working with TipRanks
Follow Us
TME Pharma N.V. (FR:ALTME)
:ALTME
ALTME Stock Chart & Stats
€0.06
<€0.01(2.26%)
At close: 4:00 PM EST
€0.06
<€0.01(2.26%)
Day’s Range― - ―
52-Week Range€0.05 - €0.15
Previous CloseN/A
Volume26.06K
Average Volume (3M)547.76K
Market Cap
€7.53M
Enterprise Value€7.36M
Total Cash (Recent Filing)€2.06M
Total Debt (Recent Filing)€1.89M
Price to Earnings (P/E)―
Beta-0.05
Next Earnings
Apr 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding94,188,980
10 Day Avg. Volume795,319
30 Day Avg. Volume547,758
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.27
Price to Sales (P/S)107.95
P/FCF Ratio-0.44
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage On Balance SheetA debt-to-equity ratio of 0.03 gives TME Pharma low interest burden and greater financing flexibility. For a clinical-stage biotech that will rely on external funding, limited leverage reduces near-term refinancing risk and preserves capacity to raise equity or partner funding to progress trials.
Notable Free Cash Flow ImprovementA 69.51% improvement in free cash flow growth rate signals operational progress and better cash conversion trends. While absolute cash flow remains negative, accelerating FCF growth can extend runway, reduce future financing needs, and strengthen negotiating positions with partners or investors over the medium term.
Lean Cost Structure (small Team)A 12-person headcount suggests a lean, capital-light operational footprint common in early-stage biotech. Lower fixed overhead enables management to allocate scarce resources toward R&D and trials, helping preserve runway and adapt spending as clinical needs evolve over the coming months.
Bears Say
Persistently Negative Margins And LossesSustained negative gross and net margins indicate the company is not yet operationally profitable. Persistent losses force continuous external funding, increase dilution risk, and limit reinvestment capacity, constraining TME Pharma's ability to self-fund trials or scale without partner financing.
Negative Operating And Free Cash FlowNegative operating cash flow means core activities consume cash rather than generate it, making the company dependent on financing or partnerships to maintain operations. Ongoing cash burn increases vulnerability to market funding conditions and may force dilutive capital raises in the medium term.
Negative ROE And Prior Negative EquityNegative ROE and historical negative shareholders' equity point to structural balance sheet weakness and prior losses exceeding capital. This undermines investor confidence, can complicate future financing, and signals a higher risk profile for partners or creditors over the next several quarters.
TME Pharma N.V. News
ALTME FAQ
What was TME Pharma N.V.’s price range in the past 12 months?
TME Pharma N.V. lowest stock price was €0.05 and its highest was €0.15 in the past 12 months.
What is TME Pharma N.V.’s market cap?
TME Pharma N.V.’s market cap is €7.53M.
When is TME Pharma N.V.’s upcoming earnings report date?
TME Pharma N.V.’s upcoming earnings report date is Apr 29, 2026 which is in 71 days.
How were TME Pharma N.V.’s earnings last quarter?
TME Pharma N.V. released its earnings results on Oct 30, 2025. The company reported -€0.022 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.022.
Is TME Pharma N.V. overvalued?
According to Wall Street analysts TME Pharma N.V.’s price is currently Overvalued.
Does TME Pharma N.V. pay dividends?
TME Pharma N.V. does not currently pay dividends.
What is TME Pharma N.V.’s EPS estimate?
TME Pharma N.V.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TME Pharma N.V. have?
TME Pharma N.V. has 94,188,980 shares outstanding.
What happened to TME Pharma N.V.’s price movement after its last earnings report?
TME Pharma N.V. reported an EPS of -€0.022 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.02%.
Which hedge fund is a major shareholder of TME Pharma N.V.?
Currently, no hedge funds are holding shares in FR:ALTME
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
TME Pharma N.V.
TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. It is also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy. The company has a collaboration agreement with Merck Sharp & Dohme Corp. to study NOX-A12 combined with Keytruda and two different chemotherapy regimens as second-line therapy in patients with metastatic pancreatic cancer. The company was formerly known as NOXXON Pharma N.V. and changed its name to TME Pharma N.V. in July 2022. TME Pharma N.V. was founded in 1997 and is based in Berlin, Germany.
Technical Analysis
Valerio Therapeutics
―
―
Hybrigenics SA Class A
―
Theranexus SA
―
Plant Advanced Technologies SA
―